Uniqure N.V. (QURE) 7.85 $QURE
Will Broadcom (AVGO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:45AM CDT
Broadcom Limited (AVGO) is scheduled to report second-quarter fiscal 2016 results after the closing bell on Jun 2.
QURE: 7.85 (unch), CTRP: 41.78 (+1.17), COO: 182.10 (+0.27), AVGO: 157.36 (+2.22)
uniQure Announces Results for First Quarter 2016
GlobeNewswire - Tue May 31, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update.
QURE: 7.85 (unch)
uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:00AM CDT
- Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort -
QURE: 7.85 (unch)
uniQure to Present at Upcoming Investor Conferences in New York City
GlobeNewswire - Thu May 12, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed investor conferences in May and June, 2016.
QURE: 7.85 (unch)
uniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes
GlobeNewswire - Mon May 09, 3:24PM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's Board of Directors. Mr. Kaye, who will also chair the Company's Audit Committee, is a seasoned financial executive with over 40 years of diversified experience. The Company also announced its intention to transition from the current two-tier Supervisory Board and Management Board structure to a single Board of Directors with executive and non-executive members.
QURE: 7.85 (unch)
uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT
GlobeNewswire - Mon May 09, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and validation of new technologies to improve gene therapy as a therapeutic approach. The results were presented in poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting in Washington D.C. and highlight the progress uniQure has made in establishing optimized gene therapy delivery systems, re-administration protocols and vector technologies specifically in its key focus areas, liver/metabolism and CNS.
QURE: 7.85 (unch)
Biotech Company On The Rise
ACCESSWIRE - Tue May 03, 8:56AM CDT
New Website and Roadshow "May" Make for Huge Month for This Biotech
QURE: 7.85 (unch)
uniQure Appoints Paul Firuta as Chief Commercial Officer
GlobeNewswire - Tue May 03, 4:00AM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Paul Firuta as Chief Commercial Officer. Mr. Firuta, who held similar positions at NPS Pharmaceuticals, Inc. and ViroPharma, Inc., has 25 years of industry experience successfully commercializing products targeting rare diseases. As a key member of the leadership team, Mr. Firuta will oversee global commercial and portfolio planning, program management, and will work closely with the Company's cross-functional teams in building relationships with patient advocacy groups and key opinion leaders. He will report to Daniel Soland, Chief Executive Officer of uniQure, and be based out of the Company's Lexington, Massachusetts facility.
QURE: 7.85 (unch), ORPN: 1.64 (-0.03)
uniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
GlobeNewswire - Tue Apr 19, 1:16PM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting held in Washington D.C., May 4-7, 2016. Together with their collaborators, members of uniQure's research and development team will present data focused on progress in improving gene therapy delivery systems, re-administration protocols and vector technologies in two of uniQure's key focus areas, liver/metabolism and CNS.
QURE: 7.85 (unch)
CORRECTING and REPLACING -- uniQure Announces Results for Fourth Quarter and Financial Year 2015
GlobeNewswire - Mon Apr 04, 6:45AM CDT
In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ:QURE), the tables were not included. The corrected release follows:
QURE: 7.85 (unch)
uniQure Announces Results for Fourth Quarter and Financial Year 2015
GlobeNewswire - Mon Apr 04, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending December 31, 2015, and provided a corporate overview on its pipeline programs and operations.
QURE: 7.85 (unch)
uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
GlobeNewswire - Tue Mar 22, 10:05AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington's disease gene therapy program, AMT-130. Findings published in the current issue of the peer-reviewed journal Molecular Therapy-Nucleic Acids (www.nature.com/mtna/journal/v5/n3/index.html) provide preclinical proof of concept for uniQure's AMT-130 program and demonstrate the potential of a one-time administration of AAV5-delivered gene therapy into the central nervous system (CNS) to silence the Huntingtin gene (HTT). An inherited, mutated form of HTT causes Huntington's disease, a rare, fatal, neurodegenerative disorder that leads to severe physical and cognitive deterioration.
QURE: 7.85 (unch)
uniQure Announces Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial
GlobeNewswire - Mon Mar 14, 5:00AM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second cohort of its ongoing AMT-060-01 Phase I/II trial in hemophilia B patients. The primary objective of the second cohort is to assess the safety of the systemic administration of a higher dose of uniQure's AMT-060 gene therapy in hemophilia B patients that present with a severe or moderately-severe disease phenotype. Secondary objectives of the trial include evaluation of Factor IX (FIX) activity levels as well as evaluation of annualized bleeding rates and recombinant FIX usage.
QURE: 7.85 (unch)
uniQure N.V. (QURE) Shows Strength: Stock Moves Up 5.3%
Zacks Equity Research - Zacks Investment Research - Mon Jan 11, 7:15AM CST
uniQure N.V. (QURE) shares rose over 5% in the last trading session.
QURE: 7.85 (unch), ANIK: 52.79 (-0.51)
Xenon Outlines Key Milestones for 2016
GlobeNewswire - Mon Jan 11, 7:00AM CST
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2016.
QURE: 7.85 (unch), XENE: 7.32 (+0.17)
uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
GlobeNewswire - Thu Jan 07, 5:00AM CST
--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure's Proprietary AAV5 Vector--
QURE: 7.85 (unch)
uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
GlobeNewswire - Wed Jan 06, 3:15PM CST
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
QURE: 7.85 (unch)
Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis
ACCESSWIRE - Wed Jan 06, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2016 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), uniQure N.V. (NASDAQ: QURE), Cytokinetics Inc. (NASDAQ: CYTK), and Curis Inc. (NASDAQ: CRIS). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 05, 2016, the NASDAQ Composite ended at 4,891.43, down 0.24%, the Dow Jones Industrial Average edged 0.06% higher, to finish the day at 17,158.66, and the S&P 500 closed at 2,016.71, up 0.20%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 10.09 (-0.24), CRIS: 1.70 (unch), QURE: 7.85 (unch), ARNA: 1.62 (-0.08)
Will Broadcom (AVGO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:45AM CDT
Broadcom Limited (AVGO) is scheduled to report second-quarter fiscal 2016 results after the closing bell on Jun 2.
QURE: 7.85 (unch), CTRP: 41.78 (+1.17), COO: 182.10 (+0.27), AVGO: 157.36 (+2.22)
uniQure Announces Results for First Quarter 2016
GlobeNewswire - Tue May 31, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update.
QURE: 7.85 (unch)
uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:00AM CDT
- Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort -
QURE: 7.85 (unch)
uniQure to Present at Upcoming Investor Conferences in New York City
GlobeNewswire - Thu May 12, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed investor conferences in May and June, 2016.
QURE: 7.85 (unch)
uniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes
GlobeNewswire - Mon May 09, 3:24PM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's Board of Directors. Mr. Kaye, who will also chair the Company's Audit Committee, is a seasoned financial executive with over 40 years of diversified experience. The Company also announced its intention to transition from the current two-tier Supervisory Board and Management Board structure to a single Board of Directors with executive and non-executive members.
QURE: 7.85 (unch)
uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT
GlobeNewswire - Mon May 09, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and validation of new technologies to improve gene therapy as a therapeutic approach. The results were presented in poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting in Washington D.C. and highlight the progress uniQure has made in establishing optimized gene therapy delivery systems, re-administration protocols and vector technologies specifically in its key focus areas, liver/metabolism and CNS.
QURE: 7.85 (unch)
Biotech Company On The Rise
ACCESSWIRE - Tue May 03, 8:56AM CDT
New Website and Roadshow "May" Make for Huge Month for This Biotech
QURE: 7.85 (unch)
uniQure Appoints Paul Firuta as Chief Commercial Officer
GlobeNewswire - Tue May 03, 4:00AM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Paul Firuta as Chief Commercial Officer. Mr. Firuta, who held similar positions at NPS Pharmaceuticals, Inc. and ViroPharma, Inc., has 25 years of industry experience successfully commercializing products targeting rare diseases. As a key member of the leadership team, Mr. Firuta will oversee global commercial and portfolio planning, program management, and will work closely with the Company's cross-functional teams in building relationships with patient advocacy groups and key opinion leaders. He will report to Daniel Soland, Chief Executive Officer of uniQure, and be based out of the Company's Lexington, Massachusetts facility.
QURE: 7.85 (unch), ORPN: 1.64 (-0.03)
uniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
GlobeNewswire - Tue Apr 19, 1:16PM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting held in Washington D.C., May 4-7, 2016. Together with their collaborators, members of uniQure's research and development team will present data focused on progress in improving gene therapy delivery systems, re-administration protocols and vector technologies in two of uniQure's key focus areas, liver/metabolism and CNS.
QURE: 7.85 (unch)
CORRECTING and REPLACING -- uniQure Announces Results for Fourth Quarter and Financial Year 2015
GlobeNewswire - Mon Apr 04, 6:45AM CDT
In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ:QURE), the tables were not included. The corrected release follows:
QURE: 7.85 (unch)
uniQure Announces Results for Fourth Quarter and Financial Year 2015
GlobeNewswire - Mon Apr 04, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending December 31, 2015, and provided a corporate overview on its pipeline programs and operations.
QURE: 7.85 (unch)
uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
GlobeNewswire - Tue Mar 22, 10:05AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington's disease gene therapy program, AMT-130. Findings published in the current issue of the peer-reviewed journal Molecular Therapy-Nucleic Acids (www.nature.com/mtna/journal/v5/n3/index.html) provide preclinical proof of concept for uniQure's AMT-130 program and demonstrate the potential of a one-time administration of AAV5-delivered gene therapy into the central nervous system (CNS) to silence the Huntingtin gene (HTT). An inherited, mutated form of HTT causes Huntington's disease, a rare, fatal, neurodegenerative disorder that leads to severe physical and cognitive deterioration.
QURE: 7.85 (unch)
uniQure Announces Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial
GlobeNewswire - Mon Mar 14, 5:00AM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second cohort of its ongoing AMT-060-01 Phase I/II trial in hemophilia B patients. The primary objective of the second cohort is to assess the safety of the systemic administration of a higher dose of uniQure's AMT-060 gene therapy in hemophilia B patients that present with a severe or moderately-severe disease phenotype. Secondary objectives of the trial include evaluation of Factor IX (FIX) activity levels as well as evaluation of annualized bleeding rates and recombinant FIX usage.
QURE: 7.85 (unch)
uniQure N.V. (QURE) Shows Strength: Stock Moves Up 5.3%
Zacks Equity Research - Zacks Investment Research - Mon Jan 11, 7:15AM CST
uniQure N.V. (QURE) shares rose over 5% in the last trading session.
QURE: 7.85 (unch), ANIK: 52.79 (-0.51)
Xenon Outlines Key Milestones for 2016
GlobeNewswire - Mon Jan 11, 7:00AM CST
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2016.
QURE: 7.85 (unch), XENE: 7.32 (+0.17)
uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
GlobeNewswire - Thu Jan 07, 5:00AM CST
--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure's Proprietary AAV5 Vector--
QURE: 7.85 (unch)
uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
GlobeNewswire - Wed Jan 06, 3:15PM CST
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
QURE: 7.85 (unch)
Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis
ACCESSWIRE - Wed Jan 06, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2016 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), uniQure N.V. (NASDAQ: QURE), Cytokinetics Inc. (NASDAQ: CYTK), and Curis Inc. (NASDAQ: CRIS). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 05, 2016, the NASDAQ Composite ended at 4,891.43, down 0.24%, the Dow Jones Industrial Average edged 0.06% higher, to finish the day at 17,158.66, and the S&P 500 closed at 2,016.71, up 0.20%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 10.09 (-0.24), CRIS: 1.70 (unch), QURE: 7.85 (unch), ARNA: 1.62 (-0.08)
